Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9

#Editors Picks @eular_org @ARD_BMJ @ACR_Journals Can #rheumatologists effectively #dx of #ankylosing #spondylitis? 👍 552 pts - 1/3 axSpA w high certainty Certainty of #dx changed over time 2 features #sacroileitis good #nSAID response #EULAR2024 @RheumNow https://t.co/NN3GZTmgn9

• https://twitter.com/Janetbirdope/status/1801219333495849335/photo/1
• https://twitter.com/Janetbirdope/status/1801219333495849335/photo/1

10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych

• https://twitter.com/i/web/status/1801186984502640804
• https://twitter.com/synovialjoints/status/1801186984502640804/photo/1
• https://twitter.com/synovialjoints/status/1801186984502640804/photo/1

Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn

• https://twitter.com/synovialjoints/status/1800920604838924393/photo/1

Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC

• https://twitter.com/synovialjoints/status/1800919956827074731/photo/1
• https://twitter.com/synovialjoints/status/1800919956827074731/photo/1

SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4

• https://twitter.com/synovialjoints/status/1800918388690108811/photo/1

Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21

• https://twitter.com/synovialjoints/status/1800915408175927352/photo/1

Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz

• https://twitter.com/synovialjoints/status/1800913941041967564/photo/1

In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/wMasGSZj2o

• https://twitter.com/synovialjoints/status/1800910597405782403/photo/1
• https://twitter.com/synovialjoints/status/1800910597405782403/photo/1

💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

• https://twitter.com/DrMiniDey/status/1800883089377562909/photo/1
• https://twitter.com/DrMiniDey/status/1800883089377562909/photo/1

Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6

• https://twitter.com/synovialjoints/status/1800879381436674257/photo/1
• https://twitter.com/synovialjoints/status/1800879381436674257/photo/1

Ankylosing spondylitis Tx w/ Tofa- How quick do they respond? Post hoc analysis 269 pts: - 4 wks for Pain >30% - 4 wks for ASDAS improved ≥ 1.1 points - 8-24 wks for ≥ 50% improved pain, enthesitis, AM stiffness, BASDAI & fatigue https://t.co/YOZgRLfPNc https://t.co/egkG76gz2E https://t.co/ZknXhKE0N4

• Time to improvement of pain, morning stiffness, fatigue, and disease activity i…
• https://buff.ly/3wXxDw9